CARGO Therapeutics is a company dedicated to developing best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access. The company is focused on addressing important drivers of resistance to first-generation cell therapies, providing clinics with a new generation of cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. CARGO is on a mission to outsmart cancer by pursuing novel solutions to achieve better cancer treatment outcomes and experiences, including overcoming manufacturing, supply constraints, slow turnaround time and reimbursement hurdles.